CATALYST PHARMACEUTICALS INC (CPRX) Stock News
NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock - Currency: USD
CPRX Latest News, Press Relases and Analysis
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for high Growth Investing Strategies?
A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET...
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why.
A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why.
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against other best Russell 2000 stocks to buy according to Wall Street analysts. Since President Trump announced new tariffs, the […]
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a rare, debilitating and life-shortening neuromuscular disease1 Upon approval, vamorolone would be the first and only treatment...
Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)
A fundamental and technical analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing?
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. Compared to the S&P 500's (SNPINDEX: ^GSPC) 4.8% tumble, Catalyst Pharmaceuticals' (NASDAQ: CPRX) 1.5% drop was mild, as was Veeva Systems' (NYSE: VEEV) 2% slide.
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?
Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 Growth Index generated a return of 1.7% in the fourth quarter, bringing the yearly returns to 15.2%. The portfolio generated positive returns in the fourth quarter […]
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
The drugmaker confirmed there's a strong market for two of its treatments.
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET...